

~~A2~~
12. (Amended) An enhancer for activity of an antitumor agent, comprising the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5, as an active ingredient.

~~A3~~
14. (Amended) An agent for abrogating accumulation action at the G2 or S stage of the cell cycle, comprising the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5, as an active ingredient.

15. (Amended) An antitumor agent comprising at least one staurosporin derivative or pharmaceutically acceptable salt thereof according to any one of claims 2 to 5.

~~Sub B1~~
16. (Amended) A pharmaceutical composition comprising at least one staurosporin derivative or pharmaceutically acceptable salt thereof according to any one of claims 2 to 5.

~~Sub B1~~
23. (Amended) A method for treating a malignant tumor, comprising the step of administering a therapeutically effective amount of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5.

~~A4~~
24. (Amended) A method for enhancing the activity of an antitumor agent, comprising the step of administering a therapeutically effective amount of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5.

25. (Amended) A method for abrogating accumulation action at the G2 or S stage of the cell cycle, comprising the step of administering a therapeutically effective

amount of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5.

26. (Amended) Use of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5 for the manufacture of an antitumor agent.

27. (Amended) Use of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5 for the manufacture of an enhancer for activity of an antitumor agent.

28. (Amended) Use of the staurosporin derivative or the pharmaceutically acceptable salt thereof according to any one of claims 2 to 5 for production of an agent for abrogating accumulation action at the G2 or S stage of the cell cycle.

REMARKS

The claims have been amended to correct their dependency and conformity with accepted U.S. practice. No new matter has been added.

Entry hereof is earnestly solicited.

10030618-01102